European health leaders urge action at Gastein conference amid policy concerns

Auer also pointed to capricious U.S. health policies, including efforts to reduce domestic drug prices, as a source of global uncertainty that impacts investment decisions by drugmakers, potentially diverting investment towards China. He suggested that European health systems could be strengthened by a willingness to pay more for products like generics to secure supply chains.

Discussions at the conference are expected to heavily feature the pharmaceutical industry, with U.S. policies and European drug pricing serving as underlying themes in debates on health security, accessibility, and competitiveness. Auer referenced the Draghi report, which proposed measures to enhance competitiveness over two years ago, questioning the substantial implementation of its recommendations given worsening economic data.

Furthermore, Auer voiced concerns about the lack of action to protect health infrastructure, advocating for intelligence sharing and enhanced cooperation between defense and health sectors to bolster pharmaceutical supply chains and reduce reliance on external sources, especially in light of evolving warfare tactics like cyberattacks and drones.

Separately, lawmakers in the EU public health committee adopted a report on cancer, pushing for dedicated funding in the next multiannual financial framework, increased focus on prevention, and equitable access to cancer screening, diagnosis, and treatment across the EU. The report faced controversy over its wording on alcohol consumption, with the Association of European Cancer Leagues stating that referring to "levels exceeding scientifically established health recommendations" implies a safe threshold, which they deem misleading.

MEPs also voted in favor of a legislative initiative resolution to improve rare cancer diagnosis, ensure equal treatment access, and enhance patient care for rare diseases, which affect millions across Europe, disproportionately children. The committee's recommendations will be put to a vote at the next European Parliament plenary session.

Meanwhile, a European Parliament event exploring the role of wine in health policy, organized by the European Committee of Wine Companies and MEP Dario Nardella, took place on World Heart Day. Civil society groups criticized the event as inappropriate and poorly timed, arguing it gives commercial interests undue influence on public health policy. Nardella and Ignacio Sánchez Recarte, secretary general of the European Committee of Wine Companies, defended the event as a necessary discussion on evidence-based policymaking and moderate consumption within a balanced lifestyle, with Nardella stating the timing was a coincidence.